| Authors: |
Zhang W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Muftuoglu M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Basyal M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Togashi N; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Iwanaga K; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Tanzawa F; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Numata M; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Bixby DL; Hematologic Oncology, University of Michigan Medical School, Ann Arbor, Michigan., Erba HP; Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina., Podoltsev N; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Schiller GJ; Hematologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California., Kumar P; Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Lesegretain A; Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Isoyama T; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Seki T; Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
